<DOC>
	<DOCNO>NCT01111318</DOCNO>
	<brief_summary>The main objective study assess effect mild , moderate severe hepatic impairment pharmacokinetics , safety tolerability BI 10773 follow oral administration BI 10773 single dose .</brief_summary>
	<brief_title>Pharmacokinetics Empagliflozin ( BI 10773 ) Patients With Impaired Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Healthy male female . Hepatically impaired male female subject . Age : 18 75 year , BMI : 1834 kg/m2 Creatinine clearance &gt; 80 mL/min ( except patient severe hepatic impairment , see exclusion criterion . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : Healthy subject ( group 1 ) 1 . Significant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder judge investigator . 2 . Relevant gastrointestinal tract surgery . 3 . Diseases central nervous system psychiatric disorder relevant neurological disorder . 4 . History relevant orthostatic hypotension , faint spell blackout ; systolic blood pressure &lt; 100 &gt; 160 mm Hg , diastolic blood pressure &lt; 60 &gt; 100 mm Hg , pulse rate &lt; 50 &gt; 100 1/min . 5 . Chronic relevant acute infection . 6 . History allergy/hypersensitivity . 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial . 8 . Use within 10 day prior administration trial drug might reasonably influence result trial base knowledge time protocol preparation 9 . Participation another trial investigational drug within 2 month multiple dose study within 1 month single dose study . 10 . Smoker ( 10 cigarette 3 cigar 3 pipe per day ) . 11 . Inability refrain smoking confine study site trial day . 12 . Alcohol abuse , drug abuse . 13 . Veins unsuited iv puncture either arm . 14 . Blood donation ( 100 mL within four week prior administration trial ) . 15 . Excessive physical activity ( within 48 hour prior trial trial ) . 16 . Any laboratory value outside reference range clinical relevance . 17 . Inability comply dietary regimen study centre . 18 . Subjects able understand comply protocol requirement , instruction protocolstated restriction . Hepatically impaired subject ( group 24 ) : 19 . Decompensated gastrointestinal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . 20 . For patient severe liver impairment ( ChildPugh C ) : Severe concurrent renal dysfunction ( e.g. , due hepatorenal syndrome ) creatinine clearance &lt; 40mL/min . 21 . Relevant gastrointestinal tract surgery . 22 . Diseases central nervous system psychiatric disorder relevant neurological disorder . 23 . Chronic relevant acute infection . 24 . History allergy/hypersensitivity . 25 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial . 26 . Use within 10 day prior administration trial drug might reasonably influence result trial base knowledge time protocol preparation . Comedication known inhibit induce Pglycoprotein ( quinidine , cyclosporine , amiodarone ) allow . In dubious case , case case decision make consultation sponsor . 27 . Participation another trial investigational drug within 2 month multiple dose study within 1 month single dose study . 28 . Smoker ( 10 cigarette 3 cigar 3 pipe per day ) . 29 . Inability refrain smoking confine study site trial day . 30 . Alcohol abuse , Drug abuse . 31 . Blood donation ( 100 mL within four week prior administration trial ) . 32 . Excessive physical activity ( within 48 hour prior trial trial ) . 33 . Clinically relevant laboratory abnormality . 34 . Inability comply dietary regimen study centre . 35 . Subjects able understand comply protocol requirement , instruction protocolstated restriction For female subject group : 36 . Pregnancy 37 . Positive pregnancy test 38 . No adequate contraception study 2 month study completion . 39 . Lactation period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>